

1 Title: Target attainment of extended-interval dosing of tobramycin in patients less than five years  
2 of age with cystic fibrosis: A pharmacokinetic analysis.

3

4 Authors: Kevin J Downes, MD<sup>1-4,\*</sup>, Austyn Grim, PharmD, BCPPS<sup>5,\*</sup>, Laura Shanley, PharmD<sup>6</sup>,  
5 Ronald C Rubenstein, MD, PhD<sup>7</sup>, Athena F Zuppa, MD, MSCE<sup>2,8,9</sup>, Marc R. Gastonguay, PhD<sup>10</sup>

6

7 \*Co-first authors

8

9 <sup>1</sup> Division of Infectious, Children's Hospital of Philadelphia, Philadelphia, PA.

10 <sup>2</sup> Center for Clinical Pharmacology, Children's Hospital of Philadelphia, Philadelphia, PA.

11 <sup>3</sup> Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia,  
12 PA.

13 <sup>4</sup> Department of Pediatrics, The University of Pennsylvania Perelman School of Medicine,  
14 Philadelphia, PA.

15 <sup>5</sup> Department of Pharmacy, Texas Children's Hospital, Houston, TX.

16 <sup>6</sup> Clinical Pharmacy, Children's Hospital of Philadelphia, Philadelphia, PA.

17 <sup>7</sup> Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington University  
18 School of Medicine, St. Louis, MO.

19 <sup>8</sup> Division of Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.

20 <sup>9</sup> Department of Anesthesiology and Critical Care, The University of Pennsylvania Perelman  
21 School of Medicine, Philadelphia, PA.

22 <sup>10</sup> Metrum Research Group, Tariffville, CT.

23

24

25 **Address for correspondence:**

26 Kevin J Downes, MD

27 Children's Hospital of Philadelphia

28 Roberts Center for Pediatric Research

29 2716 South Street, Suite 10360

30 Philadelphia, PA 19146

31 Tel: 215-590-4024

32 Email: [downeskj@email.chop.edu](mailto:downeskj@email.chop.edu)

33

34 Running Title: PK of tobramycin in young children with CF

35

36 Word Counts: Abstract 245/ Main text: 4109

37

38 Abbreviations: AIC, Akaike information criterion; AUC, area under the concentration-time

39 curve; BQL, below quantification limit; CF, cystic fibrosis; CHOP, the Children's Hospital of

40 Philadelphia; CL, clearance;  $C_{max}$ , maximal concentration;  $C_{min}$ , minimum concentration; DFI,

41 drug-free interval; EID, extended interval dosing; IOV, inter-occasion variability; OFV,

42 objective function value; PD, pharmacodynamic(s); PK, pharmacokinetic(s); Q, inter-

43 compartmental clearance; TDM, therapeutic drug monitoring; VPC, visual predictive check; V1,

44 central volume; V2, peripheral volume

45

46

47

48

49 **ABSTRACT:**

50 **Background:**

51 Extended interval dosing (EID) of tobramycin is recommended for treatment of pulmonary  
52 exacerbations in adults and older children with cystic fibrosis (CF), but data are limited in  
53 patients less than 5 years of age.

54

55 **Methods:**

56 We performed a retrospective population pharmacokinetic (PK) analysis of hospitalized children  
57 with CF <5 years of age prescribed intravenous tobramycin for a pulmonary exacerbation from  
58 March 2011 to September 2018 at our hospital. Children with normal renal function who had  $\geq 1$   
59 tobramycin concentration available were included. Nonlinear mixed effects population PK  
60 modeling was performed using NONMEM<sup>®</sup> using data from the first 48 hours of tobramycin  
61 treatment. Monte Carlo simulations were implemented to determine the fraction of simulated  
62 patients that met published therapeutic targets with regimens of 10-15 mg/kg/day once daily  
63 dosing.

64

65 **Results:**

66 Fifty-eight patients received 111 tobramycin courses (range 1-9/patient). A 2-compartment  
67 model best described the data. Age, glomerular filtration rate, and vancomycin coadministration  
68 were significant covariates on tobramycin clearance. The typical values of clearance and central  
69 volume of distribution were  $0.252 \text{ L/hr/kg}^{0.75}$  and  $0.308 \text{ L/kg}$ , respectively. No once daily  
70 regimens achieved all pre-specified targets simultaneously in >75% of simulated subjects. A

71 dosage of 13 mg/kg/dose best met the predefined targets of  $C_{\max} >25$  mg/L and  $AUC_{24}$  of 80-120  
72 mg\*h/L.

73

74 Conclusions:

75 Based on our population PK analysis and simulations, once daily dosing of tobramycin would  
76 not achieve all therapeutic goals in young patients with CF. However, extended-interval dosing  
77 regimens may attain therapeutic targets in the majority of young patients.

78

79 **INTRODUCTION:**

80 Pediatric patients with cystic fibrosis (CF) commonly experience pulmonary exacerbations (PEx)  
81 for which they receive antimicrobial therapy. Tobramycin, an aminoglycoside, is commonly  
82 used as first-line treatment for patients with CF experiencing a PEx. The CF Foundation  
83 recommends extended interval dosing (EID) for tobramycin (and other aminoglycosides) to  
84 optimize effectiveness (concentration-dependent killing) and reduce the likelihood of safety  
85 concerns such as nephrotoxicity.<sup>1</sup> Although EID has been evaluated, and appears effective and  
86 safe in patients 5 years of age and older,<sup>2</sup> there are limited data to support EID for tobramycin in  
87 CF patients less than 5 years of age.

88  
89 Therapeutic drug monitoring (TDM) can improve both the efficacy and safety of  
90 aminoglycosides. These drugs are concentration-dependent antibiotics with post-antibiotic  
91 effects,<sup>3</sup> but are also associated with a variety of dose- and duration-dependent toxicities  
92 including nephrotoxicity and ototoxicity. By monitoring aminoglycoside concentrations,  
93 providers can adjust doses to ensure that patients receive therapeutic peak serum drug  
94 concentrations and appropriate trough concentrations to potentially minimize toxicity.<sup>4</sup> Providers  
95 can also use TDM to determine the drug-free interval (DFI) - the duration of time the drug is  
96 undetectable - and ensure that the frequency of drug dosing is suitable. Currently, our institution  
97 utilizes once-daily dosing (i.e. EID) of tobramycin for patients with CF 5 years of age and older  
98 and every eight-hour dosing for patients less than 5 years of age given the limited data for  
99 tobramycin EID in these younger patients with CF.

100

101 The optimal initial dose for tobramycin when using EID in young children is unknown. As such,  
102 there are concerns about both over- and under-dosing. Younger patients may clear drug more  
103 quickly, putting them at a higher risk of inadequate antibiotic therapy when extended dosing  
104 intervals are used. Alternatively, large initial doses could result in high initial tobramycin  
105 concentrations and result in toxicity. Therefore, informed dosing guidance for tobramycin in  
106 children is important. While Arends and colleagues were the first to specifically evaluate EID in  
107 a young CF patient population,<sup>5</sup> their study calculated pharmacokinetic (PK) parameters in  
108 individual subjects using noncompartmental methods (i.e. algebraic equations).<sup>5</sup> This analytic  
109 approach using measured drug concentrations can be subject to bias since it does not account for  
110 measurement error or inter- or intra-subject variability.

111  
112 The primary objective of the current study was to utilize a population PK analysis approach to  
113 determine the suitability of empiric tobramycin EID in patients less than 5 years of age. Since  
114 TDM can be used to guide dosing during therapy, we sought to evaluate early (within 48 hours)  
115 PK parameters and assess attainment of CF Foundation-recommended goal tobramycin serum  
116 concentrations and DFI through simulations. Secondary objectives of this study were to quantify  
117 population PK parameters, including typical values and random inter-individual and residual  
118 variabilities, identify important covariates that affect early tobramycin PK, and define drug  
119 concentrations attained with EID tobramycin in patients less than 5 years of age with CF.  
120 Furthermore, using simulations, we sought to compare target attainment from model predictions  
121 to what could be expected in clinical practice using standard TDM approaches.

122

123 **METHODS:**

124 *Study Design*

125 This was a retrospective, observational study of children with CF less than 5 years of age  
126 prescribed intravenous (IV) tobramycin therapy for a PEx. All hospitalized children who  
127 received IV tobramycin therapy for standard-of-care treatment between March 1<sup>st</sup>, 2011 and  
128 September 1<sup>st</sup>, 2018 at CHOP and had at least one tobramycin concentration measurement  
129 performed for TDM were eligible for inclusion. Patients with renal impairment, defined as an  
130 estimated glomerular filtration rate (eGFR)  $<60$  mL/min/1.73m<sup>2</sup> calculated by bedside Schwartz  
131 equation,<sup>6</sup> who received extracorporeal membrane oxygenation (ECMO), with a postmenstrual  
132 age of less than 44 weeks, or who received concurrent nebulized tobramycin were excluded. The  
133 clinical team determined tobramycin dosing regimens and timing of tobramycin concentration  
134 measurements for TDM. The hospital formulary-recommended starting dose for patients less  
135 than 5 years of age at CHOP was 3.3 mg/kg/dose IV every 8 hours given as a 30-minute  
136 infusion. Peak and trough measurements were routinely obtained following the third dose.

137  
138 Patients were included into the study for all tobramycin treatment courses received during the  
139 study period. Since we were interested in empiric tobramycin dosing for this study, only drug  
140 concentrations obtained within the first 48 hours of tobramycin therapy were included. The  
141 CHOP Institutional Review Board approved of this study with a waiver of informed consent.

142

143 *Data collection*

144 Electronic medical records were reviewed for collection of demographic and biometric  
145 characteristics, serum creatinine, concurrent medications, tobramycin dosing information, and  
146 tobramycin concentrations. Data were collected in Excel (Microsoft Corp., Redmond, WA).



147 Tobramycin measurements were performed in the CHOP Chemistry Laboratory (CLIA-certified)  
148 using competitive immunoassay (VITROS® Chemistry Products TOBRA Reagent, Ortho-  
149 Clinical Diagnostics, Inc., Rochester, NY) throughout the study period. The lower limit of  
150 quantification of this assay was 0.6 mg/L.

151

### 152 *Data analysis*

153 **Base model:** Population PK analyses were conducted using nonlinear mixed-effects modeling  
154 with NONMEM® software v7.4 and the PDx-Pop v5.2.1 interface (ICON plc. Dublin, Ireland).  
155 With prior knowledge on the compartmental disposition of tobramycin,<sup>7</sup> we sought to develop a  
156 2-compartment model with first-order elimination. Since our study relied on TDM peak and  
157 trough data, we recognized that the current study design would not support estimation of  
158 parameters for the known tobramycin 2-compartment pharmacokinetic model disposition. Given  
159 that, a literature review identified published extensively sampled tobramycin PK data that could  
160 serve to support estimation of the current pediatric population PK model parameters and  
161 covariance terms.<sup>8</sup> This prior information was quantified by estimating the population PK model  
162 parameters for the literature data. The prior knowledge was formally incorporated in the current  
163 analysis by utilizing a penalized likelihood function with parametric specification of informative  
164 prior distributions on selected parameters from the literature model, and estimation of maximum  
165 *a posteriori* probability (MAP) Bayesian population PK parameters given the current TDM data  
166 set, as has been described previously.<sup>9</sup>

167

168 Between-subject variability was modeled using exponential variability, which assumes log-  
169 normal distribution of between subject variability around a parameter. A full block covariance

170 matrix was utilized to define the between-subject random effects. Residual variability (RV) was  
171 estimated using a proportional error model. Model selection was driven by the data and based on  
172 various goodness of fit indicators, including comparisons based on the minimum objective  
173 function value (OFV), visual inspection of diagnostic scatter plots, and evaluation of estimates of  
174 population fixed and random effect parameters.

175  
176 **Handling of BQL data:** Omission of below quantification limit (BQL) data can introduce  
177 substantial bias in parameter estimates,<sup>10,11</sup> particularly when there is a large amount of missing  
178 data (>10-15%). To minimize bias associated with BQL data, we developed models using the  
179 M3 method described by Beal.<sup>12</sup>

180  
181 **Covariate selection:** Initially, covariate-parameter relationships were explored graphically and  
182 any correlations between covariates noted. Covariate model selection was then conducted by a  
183 stepwise backward elimination technique starting with a full covariate model, which was  
184 carefully constructed to avoid inclusion of collinear or correlated covariates. Based on previous  
185 population PK studies of children with CF treated with tobramycin,<sup>7</sup> covariates included *a priori*  
186 were patient age and eGFR (calculated using Schwartz equation) on CL.<sup>6</sup> Age was evaluated as a  
187 Hill function on CL, as well as an exponential covariate normalized to the population median.  
188 No covariates were tested on volume parameters due to the absence of associations in published  
189 pediatric models aside from weight.<sup>7</sup> During backwards elimination, a critical change in OFV of  
190  $\geq 6.63$  for the FOCE method (nominal  $\alpha=0.01$ ,  $df=1$ ) was used to determine covariate inclusion.

191

192 Following this initial covariate evaluation process, we then performed an exploratory covariate  
193 analyses to assess the effects of concurrent nephrotoxic medication treatment on tobramycin CL.  
194 The influence of vancomycin, ticarcillin/clavulanate, trimethoprim/sulfamethoxazole,  
195 piperacillin/tazobactam, and NSAID co-administration was evaluated using a forward selection  
196 process (a reduction in OFV of  $\geq 6.63$  for inclusion). Each nephrotoxin exposure was  
197 dichotomized (Y/N) as a time-varying covariate, allowing it to vary over the course of  
198 tobramycin. We further explored the influence of nephrotoxin exposures as a class effect by  
199 grouping agents together as: none vs  $\geq 1$  agent, and 0-1 vs  $\geq 2$  agents.

200

201 **Inter-occasion variability (IOV):** To account for multiple treatment courses for the same  
202 patient over different hospitalizations, we assessed occasion-specific random effects on the  
203 structural model parameter of CL. We defined an occasion as a unique hospitalization per  
204 subject; if a patient received multiple treatment courses during a single hospitalization, only the  
205 first treatment course was included. We compared the impact of inclusion of IOV on model fit  
206 (AIC) between the final covariate model with and without IOV, evaluated the influence of IOV  
207 on the fixed and random effects parameter estimates, and examined its impact on residual  
208 unexplained variability.

209

210 **Model performance:** Model selection was determined by evaluating goodness-of-fit diagnostic  
211 plots, comparisons of the minimum objective function value (OFV), Akaike information  
212 criterion (AIC), and precision of parameter estimates. Visual predictive checks (VPCs) were  
213 performed to assess the fit of the final covariate model. 500 VPC simulations were obtained from  
214 the observed data. Observed tobramycin data was plotted along with the 95th, 50th and 5<sup>th</sup>

215 percentiles for the simulated data sets. Data was plotted as time after dose (TAD) vs.  
216 concentration. RStudio v3.6.3 (RStudio, Inc., Boston, MA) was used for descriptive statistics and  
217 graphical evaluations.

218  
219 **Simulations:** Monte Carlo simulations were performed to project concentrations achieved with  
220 EID dosing of 10-15 mg/kg/day. Simulations were based on relevant study population  
221 characteristics (e.g. age, weight, GFR, etc.) at the start of their first tobramycin course and the  
222 final PK model estimates. A total of 500 simulations were run for each subject in the study  
223 population, generating 29,000 simulated subjects, using two approaches. First, random residual  
224 variability was fixed to 0 to allow our simulations to reflect only random between subject PK  
225 variability within the population. Second, we included the random residual variability from our  
226 population PK model to better reflect variability present within a clinical sample observation  
227 context.

228  
229 **Target attainment:** Using the simulation output, we then determined how often simulated  
230 subjects met the following *a priori* goal parameters set forth by the CF Foundation for EID<sup>1</sup>:  
231 tobramycin peak ( $C_{max}$ ) concentration of  $\geq 25$  mg/L, tobramycin trough ( $C_{min}$ ) concentration of  
232  $< 0.6$  mg/L, DFI of  $< 11$  hours, and a 24-hour area under the curve ( $AUC_{24}$ ) of 80-120 mg\*h/L.  
233 Since increased tobramycin exposure is associated with nephrotoxicity, we further determined  
234 the proportion of simulated subjects with an  $AUC_{24} > 120$  mg\*h/L. Target attainment was  
235 assessed following the 2<sup>nd</sup> EID dose in two ways.

236

237 First, using the simulations with zero residual variability,  $C_{\max}$ ,  $C_{\min}$ , and DFI targets were  
238 determined directly from the simulated concentrations, while  $AUC_{24}$  was calculated using the  
239 equation,  $AUC_{24} = \text{daily dose}/CL$ , using each simulated subject's dose and CL estimates. This  
240 equation assumes drug is at steady-state, which we felt was a reasonable assumption for patients  
241 receiving EID. This approach is called the "Simulation Output" approach in results below.  
242 Second, using the simulations that incorporated residual variability from our population PK  
243 model, we performed log-linear regression on simulated concentrations at 3 and 8 hours to  
244 calculate  $AUC_{24}$ ,  $C_{\max}$ ,  $C_{\min}$ , and DFI targets. The equations used for this approach are shown in  
245 the Supplemental Materials. The log-linear approach is used clinically for TDM at many  
246 institutions,<sup>13</sup> including ours, so this approach was called the "TDM Approach." The results of  
247 these two methods demonstrate differences between model expectations and clinical calculations  
248 in a real-world setting.

249

## 250 **RESULTS:**

### 251 *Study population*

252 Sixty-one patients received 115 tobramycin courses during the study period. Four courses in 3  
253 patients were excluded (two in premature infants, two with no tobramycin concentrations  
254 obtained). Thus, 58 patients receiving 111 tobramycin courses were included. **Table 1** displays  
255 baseline characteristics of the study population during their first course and all courses during the  
256 study. The median age of patients at the initiation of therapy was 2.2 years (IQR: 1.2-4). Thirty-  
257 five subjects received one tobramycin course during the study period, 13 received two courses,  
258 and 10 received three or more courses. Two-hundred twenty-eight tobramycin serum  
259 concentrations were collected; 4 concentrations were excluded due to the samples being

260 mistimed. Of 224 tobramycin concentrations included, 53 (23.7%) were reported as BQL.

261 **Figure 1** depicts the distribution of tobramycin serum concentrations in relation to time after  
262 dose.

263

#### 264 *Model development*

265 Due to the timing of TDM sampling in our dataset (i.e. peaks and troughs), we utilized prior  
266 information from adult CF patients to inform initial parameter estimates for Q and V2. We  
267 identified a published, standard two-stage PK analysis that included rich sampling in 6 adult CF  
268 patients treated with 3.3 mg/kg thrice daily tobramycin.<sup>8</sup> Because all model parameters were not  
269 reported in this publication, we used WebPlotDigitizer<sup>14</sup> to extract the concentration-time data of  
270 each subject in Figure 2 of this published model.<sup>8</sup> We then constructed a dataset for analysis in  
271 NONMEM, using median population weight for each subject, to derive initial Q and V2  
272 estimates for our model. Given poor estimation of between-subject random effects for Q and V2  
273 during base model development, they were fixed to 0 for these parameters.

274

275 Clearance (CL) and inter-compartmental clearance (Q) were allometrically scaled for weight to  
276 0.75, normalized to 70-kg, while central (V1) and peripheral (V2) volume parameters were  
277 scaled linearly for weight, normalized to 70-kg.<sup>15</sup> The results of the covariate selection process  
278 are shown in **Supplemental Table 1**. Age and eGFR were included in the model *a priori*, based  
279 on prior published models.<sup>7</sup> Concomitant receipt of vancomycin was also informative on CL in  
280 the forward stepwise approach. When evaluating IOV, the addition of IOV increased the AIC of  
281 the model, had no impact on inter-individual random effects on CL and V, and did not change  
282 the point estimates of the model parameters. Additionally, IOV minimally reduced the residual

283 unexplained variability of the model from 33.4% to 32.8% and led to an increase in the percent  
284 relative standard error for each parameter estimate, suggesting that inclusion of IOV did not  
285 improve model fit. Therefore, IOV was not included in our final model.

286  
287 The parameter estimates for the final model are shown in **Table 2**, along with bootstrap estimates  
288 (n=1000 replications) of parameters with 95% confidence intervals. Additional bootstrap  
289 analyses were performed (n=500) with stratification by receipt of vancomycin, by age (<1 year,  
290 2-3 years, or 4+ years), and by eGFR (<100, 100-199, 200+ mL/min/m<sup>2</sup>). In each case, the model  
291 parameter estimates were within the 95% confidence intervals of the bootstrap estimates. The  
292 associated diagnostic plots for the final model are shown in **Figure 2**.

293  
294 In the final model, the typical value of CL for our population was 0.252 L/hr/kg<sup>0.75</sup> (95% CI:  
295 0.233 – 0.271), V1 was 0.308 L/kg (95% CI: 0.264 - 0.353), Q was 0.195 L/hr/kg<sup>0.75</sup> (95% CI:  
296 0.171 – 0.219), and V2 was 0.096 L/kg (95% CI: 0.81 – 0.110). Concomitant receipt of  
297 vancomycin was associated with a 29.2% (95% CI: 3.7-55.7%) reduction in tobramycin CL,  
298 although vancomycin was administered to only 5 patients during 8 tobramycin courses.

299 **Supplemental Figure 1** displays the VPCs for the final covariate model. The median and 5<sup>th</sup> and  
300 95<sup>th</sup> percentiles of the predicted tobramycin concentrations fit closely to the observed data,  
301 suggesting a good model fit.

302  
303 *Target Attainment*

304 Monte Carlo simulations were performed for tobramycin dosing regimens of 10-15 mg/kg once  
305 daily. Due to the small number of patients in our original study population who received

306 concomitant vancomycin treatment, all simulated patients did not receive vancomycin. **Table 3**  
307 reports the proportion of simulated patients achieving the goal parameters of EID.

308  
309 When assessing attainment of targets determined directly from the Simulation Output approach  
310 (i.e. using simulated concentrations and clearance estimates; no residual variability), all  
311 simulated patients achieved the  $C_{\min}$  goal of  $<0.6$  mg/L. And, more than 75% of simulated  
312 patients achieved the  $C_{\max}$  goal of  $>25$  mg/L with 11-15 mg/kg/day dosing regimens. No EID  
313 regimens achieved the AUC target (80-120 mg•h/L) in  $>75\%$  of simulated patients. More than  
314 75% of simulated patients had an AUC  $>80$  mg•h/L with dosing of 12-15 mg/kg/day, although  
315 an increasing proportion of simulated subjects' AUC exceeded 120 mg•h/L at higher dosages.  
316 Across all 5 targets, a dosage of 13 mg/kg had the highest average target attainment (79.8%),  
317 followed by 12 mg/kg (78.5%) and 14 mg/kg (78.4%).

318  
319 There were substantial differences in target attainment when the TDM Approach was assessed  
320 (i.e. log-linear regression on simulated concentrations at 3- and 8-hours; incorporated residual  
321 variability). In general, all targets were less often met using the log-linear approach compared to  
322 model expectations. The differences were most significant for  $C_{\max}$  and AUC targets. At a dose  
323 of 13 mg/kg, 42% fewer simulated subjects met the  $C_{\max}$  target using the log-linear estimation  
324 approach compared to the simulation output, while 26% fewer met the AUC<sub>24</sub> target of 80-120  
325 mg•h/L.

326

327 **DISCUSSION:**



328 This retrospective, population PK study analyzed the applicability of EID for IV tobramycin in  
329 CF patients less than five years of age, and compared attainment of therapeutic targets in  
330 simulated patients according to CF Foundation guidelines.<sup>1</sup> Our patient cohort included a wide  
331 variety of CF patients in terms of age and prior tobramycin exposures. Our simulations suggest  
332 that EID tobramycin would not attain all recommended therapeutic goals in a significant  
333 majority (>75%) of patients with CF less than five years of age. However, a dosage of 13  
334 mg/kg/day had the highest probability of target attainment across all 5 targets evaluated and  
335 would be the optimal EID dosing regimen, according to our simulations. This dose met the  $C_{\max}$   
336 and  $C_{\min}$  targets in >90% of simulated subjects, while also achieving the time undetectable and  
337  $AUC_{24}$  targets in >50% and >70%, respectively.

338  
339 EID can maximize the concentration-dependent effectiveness of tobramycin, while minimizing  
340 its risk of renal toxicity associated with accumulation of drug within proximal tubule cells in  
341 setting of sustained exposure.<sup>16</sup> EID tobramycin in patients older than five years of age has  
342 comparable efficacy and improved safety compared to conventional dosing in older  
343 children,<sup>2,17,18</sup> but data in younger children are limited. Arends and colleagues retrospectively  
344 evaluated tobramycin EID in 31 CF patients less than 6 years of age,<sup>5</sup> and found that eight out of  
345 the 29 patients evaluated for nephrotoxicity developed kidney injury according to pediatric  
346 RIFLE definitions;<sup>19</sup> this is a higher rate than reported in other studies of acute kidney injury  
347 (AKI) in older children with CF treated with tobramycin,<sup>20</sup> although only 2 patients had  
348 increases in serum creatinine of  $\geq 0.2$  mg/dL,<sup>5</sup> which could be considered a clinically significant  
349 change. Although these authors concluded that dosing of tobramycin at 12 mg/kg/dose once  
350 daily would achieve recommended peak concentrations, the effectiveness of this EID has not

351 been fully evaluated in young children and remains an important question. Based on our  
352 simulations, a dosage of 13 mg/kg/dose appears optimal, but prospective studies are needed.  
353  
354 We focused on tobramycin PK in the first two days of treatment to determine if EID would be  
355 appropriate for empiric use in young children with CF. In older children who receive EID  
356 tobramycin at our institution, TDM is routinely performed following the first or second dose, and  
357 then weekly during the course of treatment. Our analysis mirrored this approach by examining  
358 early PK and assessing target attainment on day 2. There was a substantial degree of variability  
359 between the patients within our study population. As a result, EID regimens with higher dosages  
360 obtained  $C_{\max}$  and  $C_{\min}$  concentration targets in greater than 75% of simulated patients. However,  
361 similar results were not found for the percent of patients achieving DFI and AUC goals. With  
362 extended durations of DFIs, patients may have prolonged periods of low tobramycin  
363 concentrations that put them at theoretical risk of antimicrobial failure. A large proportion of the  
364 simulated patients at higher dosages (14-15 mg/kg/day) who did not meet the AUC target did so  
365 due to supra-therapeutic AUC values ( $>120$  mg\*h/L), which could result in elevated risks of  
366 tobramycin toxicity.  
367  
368 Importantly, there were substantial differences in target attainment depending on the method  
369 used. These were most notable for estimates of  $C_{\max}$  and  $AUC_{24}$ , the two parameters that describe  
370 tobramycin exposure. In the absence of Bayesian methods, log-linear regression is often used for  
371 clinical TDM to estimate PK parameters and target attainment in individual patients.<sup>13</sup> Since this  
372 approach relies on assumptions of a one-compartment model with linear elimination,  $C_{\max}$  can be  
373 grossly underestimated for a two-compartment drug, as we found. The log-linear approach can

374 also lead to significant differences in AUC<sub>24</sub> estimates compared to Bayesian methods. In a  
375 retrospective study of 77 children with CF treated with once daily tobramycin at a mean dose of  
376 12.5 mg/kg/day, Brockmeyer et al. found that 52% met the AUC<sub>24</sub> target of 80-120 mg\*h/L after  
377 the initial dose based on log-linear regression.<sup>13</sup> This is comparable to our analyses, in which 43-  
378 44% of simulated patients given 12-13 mg/kg/day met this AUC target with log-linear  
379 regression. Brockmeyer also utilized Bayesian forecasting, based on a two-compartment model,  
380 to estimate AUC<sub>24</sub> for each subject.<sup>13</sup> Again, similar to our assessment, estimates of AUC<sub>24</sub> using  
381 Bayesian methods were higher than with log-linear regression (mean difference of 6.4  
382 mg\*h/L).<sup>13</sup> These findings have significant clinical ramifications. Dose adjustments based on  
383 log-linear regression estimates of C<sub>max</sub> and AUC<sub>24</sub> may lead to over-exposure and added risk of  
384 toxicity in some patients. Clinicians therefore need to be cognizant of the limitations of  
385 traditional TDM practices.

386  
387 Our estimates for CL and central volume are similar to previous studies involving children with  
388 CF treated with EID tobramycin. Massie et al. studied 44 children aged 9 months to 20 years  
389 given 12 mg/kg/day.<sup>21</sup> Based on a one-compartment model, they found that CL and volume of  
390 distribution were 0.103 L/h/kg and 0.267 L/kg, respectively.<sup>21</sup> Hennig et al. performed a  
391 population PK analysis of 35 patients with CF aged 0.5 to 17.8 years treated with 10 mg/kg/day  
392 of tobramycin.<sup>22</sup> Their two-compartment model estimated median population values for clearance  
393 of 6.37 L/h/70 kg and central volume of 18.7 L/70 kg,<sup>22</sup> again similar to our model's estimates  
394 (Table 2). However, in a study involving 85 children with CF 5-15 years of age by Touw et al.,<sup>23</sup>  
395 volume of distribution was larger among recipients of once daily compared to thrice daily  
396 therapy (0.401 vs 0.354 L/kg, respectively). Clearance was not reported, but elimination rate did

397 not differ by dosing regimen in this study.<sup>23</sup> So, while the findings of our study are consistent  
398 with prior reports,<sup>21,22</sup> it is possible that PK parameters could have differed in our population of  
399 young children had they actually been administered EID.

400  
401 Because TDM concentrations were collected as standard of care, approximately 28% of the  
402 tobramycin samples included in our study were reported as BQL. While we attempted to account  
403 for this using the validated M3 method described by Beal,<sup>12</sup> this may have contributed to  
404 increased variability in PK parameters in the model. Omission of BQL data can introduce  
405 substantial bias in parameter estimates. In our study, omission of BQL would result in under-  
406 estimation of CL since the vast majority of BQL data were trough measurements. The M3  
407 method estimates the likelihood that BQL data are actually below quantification limits and is  
408 associated with less bias than omission of BQL data when missing data are during the  
409 elimination phase. Thus, despite a substantial amount of BQL data in our study, we believe that  
410 our PK parameter estimates are accurate.

411  
412 Since this study was retrospective and relied on standard-of-care TDM drug concentrations,  
413 multiple additional limitations exist, which also may have contributed to variability in the model  
414 estimates. First, documentation of the duration of infusion was not a component of standard  
415 institutional practice during the study period. However, CHOP utilized standard infusion  
416 procedures, including a routine infusion time (30 minutes), which was assumed to have been  
417 used in all cases in PK modeling. Incorrect recording of the timing of tobramycin sampling or  
418 administration similarly could have affected the estimated PK parameters in the model. Any  
419 tobramycin samples that were deemed to clearly be an error (i.e. concentrations drawn during an

420 infusion, concentrations reported as undetectable within 2 hours after the infusion) were not  
421 included in the analysis. Lastly, the number of tobramycin serum samples varied greatly between  
422 patients, which could have led to differential patient contribution in the PK model.

423  
424 Overall, EID regimens optimize tobramycin efficacy while potentially lessening toxicity risk in  
425 subjects five years and older. Based on our population PK analysis and simulations, EID  
426 regimens may not achieve all recommended pharmacokinetic targets for younger children with  
427 CF. However, certain doses of EID can optimize the effectiveness and safety of tobramycin in  
428 patients less than five years of age while achieving targets in most individuals. Use of TDM will  
429 be paramount to ensure that appropriate dosing regimens are administered during prolonged  
430 courses, but clinicians should recognize that traditional TDM practices using log-linear  
431 regression methods underestimate the true  $C_{max}$  and  $AUC_{24}$  in patients. Prospective studies will  
432 be needed to validate our findings and specifically evaluate the safety and effectiveness of these  
433 regimens in CF patients less than five years of age.

434

435

436

437 **FUNDING:**

438 This study was carried out as part of our routine work. KJD is supported by the Eunice Kennedy  
439 Shriver National Institute of Child Health & Human Development of the National Institutes of  
440 Health under Award Number K23HD091365.

441

442 **TRANSPARENCY DECLARATIONS:**

443 KJD has received research support from Merck & Co., Inc. unrelated to the current work. AFZ  
444 has received research support from Eunice Kennedy Shriver National Institute of Child Health &  
445 Human Development (award numbers UG1HD063108, R21HD093369), the U.S. Department of  
446 Defense (award number W81XWH-17-1-0668), and Zelda Therapeutics, unrelated to this work.

447 The content is solely the responsibility of the authors and does not necessarily represent the  
448 official views of any of the above supporting agencies. All other authors: Nothing to declare.

449

450 **Figure Legends**

451 **Figure 1: Distribution of tobramycin measurements in relation to time after dose.** Drug

452 concentrations reported as below limit of quantification are shown in blue and plotted as 0 mg/L.

453

454 **Figure 2: Diagnostic plots for final population pharmacokinetic model.** A: Observed vs.

455 population-predicted concentrations. B: Observed vs. individual predicted concentrations. C.

456 Conditional weighted residuals (CWRES) vs. population-predicted concentrations. D. CWRES

457 vs time after dose. Observed concentrations below limit of quantification omitted.

458

459 **Supplemental Figure 1: Visual predictive check of concentrations versus time after dose.**

460 Observed tobramycin time after dose compared with the 95<sup>th</sup>, 50<sup>th</sup> and 5<sup>th</sup> percentiles for 500

461 simulated data sets. Comparison of median (solid blue line) and 5<sup>th</sup>–95<sup>th</sup> quantiles (red dashed

462 lines). The 50<sup>th</sup> percentile prediction interval is depicted as the solid blue band and the 5<sup>th</sup> and

463 95<sup>th</sup> percentile prediction intervals are depicted as red bands. Observed values below limit of

464 quantification were omitted. Simulated values <0.6 mcg/mL refit at 0.6 mcg/mL since observed

465 values cannot be quantified below this threshold.

466 **REFERENCES**

- 467 1. Flume PA, Mogayzel PJ, Jr., Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of  
468 pulmonary exacerbations. *Am J Respir Crit Care Med*. 2009;180(9):802-808.
- 469 2. Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin  
470 treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised  
471 controlled trial. *Lancet*. 2005;365(9459):573-578.
- 472 3. Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell  
473 protection. *Int J Otolaryngol*. 2011;2011:937861.
- 474 4. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. *Br J*  
475 *Clin Pharmacol*. 2012;73(1):27-36.
- 476 5. Arends A, Pettit R. Safety of Extended Interval Tobramycin in Cystic Fibrosis Patients Less an 6  
477 Years Old. *J Pediatr Pharmacol Ther*. 2018;23(2):152-158.
- 478 6. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. *Clin J*  
479 *Am Soc Nephrol*. 2009;4(11):1832-1843.
- 480 7. Bloomfield C, Staats CE, Unwin S, Hennig S. Assessing Predictive Performance of Published  
481 Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. *Antimicrob*  
482 *Agents Chemother*. 2016;60(6):3407-3414.
- 483 8. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and  
484 elimination of tobramycin administered in single or multiple daily doses in adult patients with  
485 cystic fibrosis. *J Antimicrob Chemother*. 2002;50(4):553-559.
- 486 9. Knebel W, Gastonguay MR, Malhotra B, El-Tahtawy A, Jen F, Gandelman K. Population  
487 pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with  
488 heterozygous familial hypercholesterolemia: selective use of informative prior distributions from  
489 adults. *J Clin Pharmacol*. 2013;53(5):505-516.



- 490 10. Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect  
491 models. *AAPS J.* 2009;11(2):371-380.
- 492 11. Gastonguay MR, French JL, Heitjan DF, Rogers JA, Ahn JE, Ravva P. Missing data in model-based  
493 pharmacometric applications: points to consider. *J Clin Pharmacol.* 2010;50(9 Suppl):63S-74S.
- 494 12. Beal SL. Ways to fit a PK model with some data below the quantification limit. *J Pharmacokinet*  
495 *Pharmacodyn.* 2001;28(5):481-504.
- 496 13. Brockmeyer JM, Wise RT, Burgener EB, Milla C, Frymoyer A. Area under the curve achievement  
497 of once daily tobramycin in children with cystic fibrosis during clinical care. *Pediatr Pulmonol.*  
498 2020;55(12):3343-3350.
- 499 14. Rohatgi A. WebPlotDigitizer, Version 4.3. <https://automeris.io/WebPlotDigitizer>. Published  
500 2020. Accessed 9/28/20.
- 501 15. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia  
502 in paediatric patients. *Clin Pharmacokinet.* 1997;33(5):313-327.
- 503 16. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. *Antimicrob Agents*  
504 *Chemother.* 1999;43(5):1003-1012.
- 505 17. Riethmueller J, Ballmann M, Schroeter TW, et al. Tobramycin once- vs thrice-daily for elective  
506 intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. *Infection.*  
507 2009;37(5):424-431.
- 508 18. Landmesser KB, Autry EB, Gardner BM, Bosko KA, Schadler A, Kuhn RJ. Comparison of the  
509 predictive value of area under the curve versus maximum serum concentration of intravenous  
510 tobramycin in cystic fibrosis patients treated for an acute pulmonary exacerbation. *Pediatr*  
511 *Pulmonol.* 2021;56(10):3209-3216.
- 512 19. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE  
513 criteria in critically ill children with acute kidney injury. *Kidney Int.* 2007;71(10):1028-1035.

- 514 20. Downes KJ, Rao MB, Kahill L, Nguyen H, Clancy JP, Goldstein SL. Daily serum creatinine  
515 monitoring promotes earlier detection of acute kidney injury in children and adolescents with  
516 cystic fibrosis. *J Cyst Fibros*. 2014;13(4):435-441.
- 517 21. Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children  
518 with cystic fibrosis. *J Paediatr Child Health*. 2006;42(10):601-605.
- 519 22. Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin  
520 dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. *Br J Clin*  
521 *Pharmacol*. 2008;65(4):502-510.
- 522 23. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice  
523 daily and once daily in children and adults with cystic fibrosis. *J Cyst Fibros*. 2007;6(5):327-333.

524

525

526

527

**Table 1. Characteristics of study population based on first course and all courses of tobramycin.**

| Characteristic   | First course (n=58) | All courses (n=111) <sup>a</sup> |
|--|---------------------|----------------------------------|
| Female gender, n (%)   | 25 (43%)            | 46 (41%)                         |
| Age in years, median (IQR)                                   | 2.2 (0.8 - 3.8)     | 2.6 (1.2 - 4)                    |
| Weight in kg, median (IQR)                                   | 11.2 (8.2 – 14.7)   | 12.4 (9.7 – 14.8)                |
| Height in cm, median (IQR)                                   | 85.8 (70.5 – 95.5)  | 88.1 (75 – 98)                   |
| Serum creatinine in mg/dL, median (IQR) <sup>b</sup>         | 0.3 (0.2 – 0.3)     | 0.3 (0.2 – 0.3)                  |
| GFR in ml/min/1.73m <sup>2</sup> , median (IQR) <sup>b</sup> | 126 (110– 149)      | 129 (110 – 148)                  |
| GFR < 90 ml/min/1.73m <sup>2</sup> , n (%) <sup>b</sup>      | 3 (5.2%)            | 6 (5.4%)                         |
| Dose in mg/kg/dose, median (IQR) <sup>b</sup>                | 3.2 (3.1 – 3.3)     | 3.2 (3.1 – 3.3)                  |
| Concurrent nephrotoxic medications, n (%) <sup>b,c</sup>     |                     |                                  |
| 0  | 38 (65.5)           | 70 (63.0)                        |
| 1  | 18 (31.0)           | 33 (29.7)                        |
| 2 or more  | 2 (3.4)             | 8 (7.2)                          |

<sup>a</sup> Among 58 individuals treated, 35 received 1 course, 13 received 2 courses, 4 received 3 courses, 1 received 4 courses, 2 received 5 courses, and 1 each received 7, 8 and 9 courses.

<sup>b</sup> At time of tobramycin initiation

<sup>c</sup> Concurrent nephrotoxic medications included non-steroidal anti-inflammatory medications, acyclovir, vancomycin, piperacillin/tazobactam, ticarcillin/clavulanate, and trimethoprim/sulfamethoxazole.

528

529

530

531

| <b>Table 2. Final population PK parameter estimates.</b> |          |      |                              |               |
|--|----------|------|------------------------------|---------------|
|  | Model    |      | Bootstrap estimates (n=1000) |               |
| Parameter  | Estimate | %RSE | Median                       | 95% CI        |
| $\theta_{CL}$ (L/hr/70kg)                                | 6.10     | 3.89 | 6.09                         | 5.68-6.57     |
| $\theta_{AGE}$   | 0.136    | 12.1 | 0.137                        | 0.102-0.175   |
| $\theta_{GFR}$   | 0.246    | 32.4 | 0.269                        | 0.078-0.436   |
| $\theta_{VAN}$   | 0.708    | 19.1 | 0.752                        | 0.462-1.24    |
| $\theta_{V1}$ (L/70kg)                                   | 21.6     | 7.41 | 21.5                         | 18.6-24.7     |
| $\theta_Q$ (L/hr/70kg)                                   | 4.73     | 6.24 | 4.72                         | 4.56-4.89     |
| $\theta_{V2}$ (L/70kg)                                   | 6.69     | 7.55 | 6.09                         | 5.70-7.37     |
| $\omega_{1,1}$   | 0.0296   | 17.8 | 0.0287                       | 0.0169-0.0473 |
| $\omega_{1,2}$   | 0.0325   | 32.3 | 0.0323                       | 0.0153-0.0552 |
| $\omega_{2,2}$   | 0.0633   | 28.9 | 0.0655                       | 0.0370-0.103  |
| Residual variability                                     | 0.334    | 6.89 | 0.324                        | .254-.405     |

Final model parameterized as:

$$TVCL = \theta_{CL} * [(WT/70) ^ 0.75] * (AGE/2.7 ^ \theta_{AGE}) * (GFR/128 ^ \theta_{GFR}) * (\theta_{VAN} ^ VAN)$$

$$TVV1 = \theta_{V1} * (WT/70)$$

$$TVQ = \theta_Q * [(WT/70) ^ 0.75]$$

$$TVV2 = \theta_{V2} * (WT/70)$$

A full block covariance matrix was utilized to define the inter-individual random effects ( $\omega$ ) for CL and V1. Inter-individual random effects fixed to 0 for Q and V2.

Abbreviations: CL = clearance; BSV = between subject variability; Q = inter-compartmental clearance; RSE = relative standard error; V1 = central volume; V2 = peripheral volume

532

533

**Table 3. Percentage of simulated patients meeting therapeutic targets on day 2 of treatment based on simulated concentrations.**

| Target                                      | 10 mg/kg | 11 mg/kg | 12 mg/kg | 13 mg/kg | 14 mg/kg | 15 mg/kg |
|---|----------|----------|----------|----------|----------|----------|
| <b><u>Simulation Output<sup>a</sup></u></b> |          |          |          |          |          |          |
| $C_{\max} >25$ mg/L                         | 65.6     | 79.1     | 88.2     | 93.9     | 96.8     | 98.4     |
| $C_{\min} <0.6$ mg/L                        | 100      | 100      | 100      | 100      | 100      | 100      |
| Time undetectable <11h                      | 31.2     | 38.1     | 44.9     | 51.5     | 56.8     | 62.4     |
| AUC <sub>24</sub> 80-120 mg*h/L             | 40.3     | 56.9     | 67.9     | 70.4     | 66.1     | 55.7     |
| AUC <sub>24</sub> <120 mg*h/L               | 98.8     | 96.4     | 91.4     | 83.0     | 72.3     | 68.5     |
| <b><u>TDM Approach<sup>b</sup></u></b>      |          |          |          |          |          |          |
| $C_{\max} >25$ mg/L                         | 32.9     | 39.4     | 46.3     | 51.7     | 57.0     | 61.9     |
| $C_{\min} <0.6$ mg/L                        | 95.2     | 95.1     | 94.8     | 94.2     | 94.1     | 93.3     |
| Time undetectable <11h                      | 33.7     | 37.3     | 40.7     | 43.8     | 46.7     | 49.0     |
| AUC <sub>24</sub> 80-120 mg*h/L             | 33.2     | 39.1     | 43.2     | 44.5     | 42.8     | 40.4     |
| AUC <sub>24</sub> <120 mg*h/L               | 93.4     | 89.0     | 83.0     | 76.0     | 68.3     | 60.3     |

Monte Carlo simulations (n=500) performed using study population characteristics (age, weight, GFR) at start of tobramycin course. Target attainment assessed following the second dose.

<sup>a</sup>  $C_{\max}$ ,  $C_{\min}$ , and time undetectable determined from simulated concentrations at 24.5, 48, and 37 hours, respectively. AUC<sub>24</sub> calculated using equation:  $AUC_{24} = (\text{daily dose} / CL)$ . Residual variability set to 0 during simulation process to such that results reflect only variability in population PK parameters.

<sup>b</sup> All targets calculated based on log-linear regression of simulated concentrations at 3 and 8 hours following the second dose, as is typically performed with clinical TDM. Residual variability from final population PK model included in the simulation

process to reflect real-world sources of variability.

Green shading = >75% target attainment. Yellow shading = 50-75% target attainment. Red shading = <50% target attainment

535  
536



